Kevin has over 30 years’ experience in pharmaceutical discovery and development in the fields of oncology, inflammation, immunology, cardiovascular and infectious diseases. He has served in research leadership positions in 9 international biotechnology companies including Biogen, Domantis, F-Star and Tusk Therapeutics, where he served as Chief Development Officer until its acquisition in 2018 by Roche.
Kevin holds a BSc in biological sciences and a PhD in Immunology from the University of London.